Cargando…

The clinical utility of lurasidone in schizophrenia: patient considerations

Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the United Kingdom, other European countries, the United States, and Canada. In addition to full antagonist activity at the dopamine D(2) (Ki, 1 nM) and serotonin 5-HT(2A) (Ki, 0....

Descripción completa

Detalles Bibliográficos
Autor principal:	Harvey, Philip D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425313/ https://www.ncbi.nlm.nih.gov/pubmed/25995636 http://dx.doi.org/10.2147/NDT.S68417

Ejemplares similares

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011)

Identification of clinical phenotypes in schizophrenia: the role of lurasidone
por: Riva, Marco Andrea, et al.
Publicado: (2021)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
por: Guilera, Teresa, et al.
Publicado: (2023)

Management of bipolar I depression: clinical utility of lurasidone
por: Findlay, Lillian Jan, et al.
Publicado: (2015)

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
por: Pikalov, Andrei, et al.
Publicado: (2018)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
por: Yasui-Furukori, Norio
Publicado: (2012)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
por: Miura, Itaru, et al.
Publicado: (2023)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
por: Fagiolini, Andrea, et al.
Publicado: (2022)

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
por: Harvey, Philip D., et al.
Publicado: (2016)

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
por: Javed, Afzal, et al.
Publicado: (2019)

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
por: Meltzer, Herbert Y., et al.
Publicado: (2020)

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2023)

Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia
por: Mielczarek, Z., et al.
Publicado: (2023)

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

M43. MODEL-BASED ANALYSIS OF EFFECTS OF LURASIDONE ON PROLACTIN IN SCHIZOPHRENIA PATIENTS
Publicado: (2020)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
por: Ogasa, Masaaki, et al.
Publicado: (2012)

Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy
por: Tarzian, Martin, et al.
Publicado: (2023)

Lurasidone augmentation to clozapine in treatment resistant schizophrenia: A pilot study
por: Arienti, V., et al.
Publicado: (2023)

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS
por: Tocco, Michael, et al.
Publicado: (2018)

Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
por: Jones, A., et al.
Publicado: (2022)

Lurasidone hydrochloride
por: Zhang, Hua, et al.
Publicado: (2012)

The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
por: Thomas, Jennifer E., et al.
Publicado: (2015)

A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
por: Srisurapanont, Manit, et al.
Publicado: (2021)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
por: Dymond, Amy, et al.
Publicado: (2022)

Lurasidone as a potential therapy for bipolar disorder
por: Woo, Young Sup, et al.
Publicado: (2013)

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2015)

Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
por: Restelli, Umberto, et al.
Publicado: (2020)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021)

Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report
por: Mielczarek, Zuzanna, et al.
Publicado: (2023)

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report
por: Ricci, Valerio, et al.
Publicado: (2022)

Antipsychotic treatments; focus on lurasidone
por: Sumiyoshi, Tomiki
Publicado: (2013)

Lurasidone-induced Oculogyric Crisis
por: Das, Soumitra, et al.
Publicado: (2017)

Lurasidone-induced Parkinsonism and Hyperprolactinemia
por: Suthar, Navratan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v2615id466a6rq3kofcqjqjcpt